top of page

WORK PACKAGE 7

Methodological tools using multi-criteria value methods for HTA decision-making

Objectives
  • To create an analytical framework explaining the determinants of HTA coverage recommendations from a comparative perspective

  • To generate a predictive model, and test it empirically, analysing the relative importance of different value dimensions across countries implementing HTA and across different therapeutic areas

  • To develop (a) a multidimensional value framework and (b) preference elicitation techniques to inform HTA decision-making processes relating to the evaluation of new medicines;

  • To test the multi-dimensional value framework in practice and assess its suitability for evaluating new medicines with HTA agencies and relevant stakeholders

  • To research the practical implementation of MCDA evaluations, by adapting these in alignment with responsibilities and remits currently in place across different HTA bodies 

​

Methodology
  • Use an analytical framework to identify critical determinants in the evidence submitted to HTA bodies; develop a parsimonious model that captures these determinants in a systematic way and conduct econometric analysis to identify their relevance and importance in shaping HTA recommendations

  • Structure sound multi-criteria evaluation models using participatory Delphi processes to collect views from relevant stakeholders; develop methods within a socio-technical framework for the evaluation of new medicines based on a common and transparent value metric, using both qualitative (e.g. MACBETH) and quantitative (e.g. swing weighting) approaches

  • Test empirically the proposed value framework in collaboration with three HTA bodies using a rotational design, and develop an actionable model for the evaluation of medicines across different disease areas

  • Explore multi-criteria portfolio decision models to inform resource allocation and value based pricing indices obtained through multi-variate regression analyses using MCDA scores as tools to assist HTA bodies

​

Outputs
  • Deliverable D7.1: An analytical framework outlining the determinants of HTA recommendations across settings based on primary data collection and primary analysis of secondary data (available January 2023). D7.1 Executive Summary [PDF]
     

  • Deliverable D7.2: Advancing knowledge and MCDA tools to assist HTA agencies in evaluating medicines on a common basis (available January 2023). D7.2 Executive Summary [PDF]
     

  • Deliverable D7.3: Testing the IMPACT-HTA Value Framework in collaboration with HTA agencies: Case studies on Non-Small Cell Lung Cancer and Spinal Muscular Atrophy (available January 2023). D7.3 Executive Summary [PDF]
     

  • Dataset on determinants of HTA recommendations (available January 2023) 
     

  • Dataset from the 1st Delphi process to HTA stakeholders, organized into 6 parallel panels (2 rounds), about “This aspect should be considered in the evaluation of new medicines on a common basis” (2019) (available January 2023)
     

  • Dataset from the 2nd Delphi process to HTA stakeholders, organized in a single panel (2 rounds), question “This aspect should be considered in the evaluation of new medicines on a common basis” (2019) (available January 2023)
     

  • Dataset from the Web-Delphi process to INAMI stakeholders (three rounds), about “The relevance of the following value aspects for the evaluation of new medicines in this disease context is” (2020) (available January 2023)
     

  • Dataset from the Web-Delphi process to TLV stakeholders (three rounds), about “The relevance of the following value aspects for the evaluation of new medicines in this disease context is” (2020) (available January 2023)

​

Publications

  • Oliveira MD, et al. (2019). Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. The European Journal of Health Economics 20(6): 891–918. [https://link.springer.com/article/10.1007%2Fs10198-019-01052-3] 10.1007/s10198-019-01052-3

​

Leads

Instituto Superior Técnico

Engineering and Management Department

 

London School of Economics and Political Science

LSE Health

​

Research team

Monica Oliveira (PI)

Panos Kanavos (PI)

Carlos Bana

Aris Angelis

Erica Visintin

Klára Dimitrovová

Ana Vieira

Teresa Rodrigues

Liliana Freitas

​

​

bottom of page